Adherence to Statin Treatment and Health Outcomes in an Italian Cohort of Newly Treated Patients: Results From an Administrative Database Analysis

Clinical Therapeutics

Volumn 34, Issue 1, 2012, Pages 190-199

  Degli Esposti, Luca ^a   Saragoni, Stefania ^a   Batacchi, Paolo ^b   Benemei, Silvia ^c   Geppetti, Pierangelo ^c   Sturani, Alessandra ^d   Buda, Stefano ^a   Degli Esposti, Ezio ^d  

^a Economics and Outcomes Research   (Italy)

^b Local Health Unit of Florence   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d POLICLINICO UMBERTO I   (Italy)

Author keywords

Adherence; All cause mortality; Effectiveness; Real practice; Statins; Stroke

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STROKE; STROKE PATIENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DATABASES AS TOPIC; DYSLIPIDEMIAS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ITALY; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856142605     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.12.011     Document Type: Article

References (39)

1. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999, 282:2340-2346.
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Sever P.S., Dahlöf B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
4. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
5. Glick H., Heyse J.F., Thompson D., Epstein R.S., Smith M.E., Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992, 8:719-734.
6. Pharoah P.D., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996, 312:1443-1448.
7. Pickin D.M., McCabe C.J., Ramsay L.E., et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999, 82:325-332.
8. Avorn J., Monette J., Lacour A., et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458-1462.
9. Benner J.S., Glynn R.J., Mogun H., Neumann P.J., Weinstein M.C., Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002, 288:455-461.
10. Jackevicius C.A., Mamdani M., Tu J.V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002, 288:462-467.
11. Perreault S., Blais L., Lamarre D., et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005, 59:564-573.
12. Poluzzi E., Strahinja P., Lanzoni M. Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy. Eur J Clin Pharmacol 2008, 64:425-432.
13. Andrade S.E., Kahler K.H., Frech F., Chan K.A. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006, 15:565-577.
14. ISPOR Medication Compliance and Persistence Special Interest Group (MCP) International Society for Pharmacoeconomics and Outcomes Research, Accessed May 15, 2008. http://www.ispor.org/sigs/medication.asp.
15. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43:521-530.
16. Penning-van Beest F.J., Termorshuizen F., Goettsch W.G., Klungel O.H., Kastelein J.J., Herings R.M. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007, 28:154-159.
17. Perreault S., Dragomir A., Blais L., Berard A., Lalonde L., White M. Impact of adherence to statins on chronic heart failure in primary prevention. Br J Clin Pharmacol 2008, 66:706-716.
18. Rasmussen J.N., Chong A., Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007, 297:177-186.
19. Ho P.M., Spertus J.A., Masoudi F.A., et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006, 166:1842-1847.
20. Shalev V., Chodick G., Silber H., Kokia E., Jan J., Heymann A.D. Continuation of statin treatment and all-cause mortality: a population-based cohort study. Arch Intern Med 2009, 169:260-268.
21. Ho P.M., Rumsfeld J.S., Masoudi F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006, 166:1836-1841.
22. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 2007, 16:241-249.
23. Catalan V.S., LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000, 3:417-426.
24. Kettani F.Z., Dragomir A., Côté R., et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009, 40:213-220.
25. Scardovi I., Monari P. Metodologia Statistica in Biologia e Medicina 1993, Unione Tipografico-Editrice Torinese, Torino, Italy.
26. Marubini E., Valsecchi M.G., Emmerson M. Analysing Survival Data from Clinical Trials and Observational Studies 1995, 103-159. Wiley, New York, NY.
27. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125.
28. Anker S.D., Clark A.L., Winkler R., et al. Statin use and survival in patients with chronic heart failure-results from two observational studies with 5200 patients. Int J Cardiol 2006, 112:234-242.
29. Hippisley-Cox J., Coupland C. Effect of statins on the mortality of patients with ischaemic heart disease: population based cohort study with nested case-control analysis. Heart 2006, 92:752-758.
30. Demierre M.F., Higgins P.D., Gruber S.B., Hawk E., Lippman S.M. Statins and cancer prevention. Nat Rev Cancer 2005, 5:930-942.
31. Phillips B., Aziz F., O'Regan C.P., Roberts C., Rudolph A.E., Morant S. Switching statins: the impact on patient outcomes. Br J Cardiol 2007, 14:280-285.
32. Huser M.A., Evans T.S., Berger V. Medication adherence trends with statins. Adv Ther 2005, 22:163-171.
33. Lachaine J., Rinfret S., Merikle E.P., Tarride J.E. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J 2006, 152:164-169.
34. Jones P., Kafonek S., Laurora I., Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998, 81:582-587.
35. Newman C., Tsai J., Szarek M., Luo D., Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006, 97:61-67.
36. Arca M. Atorvastatin: a safety and tolerability profile. Drugs 2007, 67(suppl 1):63-69.
37. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. Am Heart J 2007, 153:881-888.
38. Motheral B.R., Fairman K.A. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997, 19:346-366.
39. Birnbaum H.G., Cremieux P.Y., Greenberg P.E., LeLorier J., Ostrander J.A., Venditti L. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999, 16:1-8.